Enanta’s Path Forward Uncertain After RSV Failure
Despite High-Risk Studies To Come
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
